The results demonstrated that patients who switched from interferon beta (IFN beta) to Copaxone (glatiramer acetate injection) experienced a 77% reduction in annualized relapse rates (0.63 to 0.14).
This approval – the third for pemetrexed in Europe – follows an initial positive opinion issued by the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human
The Attract-1 trial is a randomized, double-blind, placebo-controlled, multicentre Phase III trial being conducted across the US, EU and other territories. With 1200 patients, it will be amongst
This is the second patent application of 2008 which was made pursuant to Kraig’s sponsored research program at the University of Notre Dame and which is subject to
At the second closing, the company sold 2,195 shares of series A convertible preferred stock for $1,000 per share, or gross proceeds of approximately $2.2 million. At the
The Endolase RFT Root Canal Therapy System and the Waterlase MD laser system are now available through the company’s North American distributor Henry Schein Dental, the Biolase direct
The grant of the European patent is expected in several weeks. Other patents related to the Antisenilin antibodies have been granted in Japan, China and elsewhere. Patent applications
There are currently over 20 marketed products using peptides protected under the patent including such cosmeceutical brands as Fusion Beauty, Smashbox, Isomers, and B Kamins. Numerous additional product
Trials will begin in mid-June, 2008 followed by the completion of necessary investigations for an investigational new drug application (IND) filing as required by the PMDA (Pharmaceutical and
Under the terms of the collaboration, Galapagos will receive an upfront payment of $400,000 and may receive research funding to support Bausch & Lomb’s further development of the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.